Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a pill replace the IV? new study tests oral ketamine with drug boosters

NCT ID NCT07462559

Knowledge-focused Sponsor: Helsinki University Central Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 1 trial in 12 healthy volunteers tests whether cannabidiol (CBD) and cobicistat (a drug that boosts other medications) can increase the amount of oral ketamine that reaches the bloodstream. Ketamine is used for treatment-resistant depression but is usually given by IV because oral doses are poorly absorbed. The study will measure drug levels and side effects over 11 hours after dosing. It is an early step toward possibly developing an effective oral ketamine treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ketamine, cannabidiol, cobicistat
What this could lead to
If successful, this could show that combining ketamine with cobicistat makes oral ketamine more reliable, potentially enabling a pill form for depression treatment.
What could go wrong
This is a very early, small study in 12 healthy people, not patients. It only measures drug levels and side effects, not depression outcomes. Results may not translate to real-world use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 12 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * written informed consent * age 18-45 years * healthy * no indications of substance abuse * acceptable values in laboratory tests: hemoglobin must be at least at the lower limit of the reference range (men 134 g/l, women 117 g/l), liver values at most at the upper limit of the reference range (P -ALAT: women below 35 U/l, men below 50 U/l; P -AFOS: 35 U/l - 105 U/l; P -GT: women less than 40 U/l, men less than 60 U/l; P -Bil: less than 20 umol/l) and in other results (B -PVKT, P -Krea, P -K and P -Na) only minor values that deviate from normal values, which according to the examining physician's assessment are clinically insignificant. Drug screening (U -Huum-PS) and in women the pregnancy test (P-hCG-tot) should be negative. * No significant abnormalities in the ECG Exclusion Criteria: * significant illness * mood disorder or suicidality * substance abuse * systolic blood pressure over 150 mmHg * conduction disorder or other significant abnormality in the ECG * smoking * regular medication, excluding contraceptives that do not contain estrogens * pregnancy or its planning or breastfeeding * less than 3 months from the previous clinical trial * less than 3 months since donating blood * significant overweight or underweight * difficult to find elbow veins * hypersensitivity to investigational drugs or excipients of medicinal products * use of natural products (such as St. John's wort).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Drug drug interaction are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Drug drug interaction

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Clinical Pharmacology

    Helsinki, Finland

More trials for these conditions

Other studies related to the condition(s) this trial covers.